Amneal lanreotide injection received U.S. Food and Drug Administration approval in a 120 mg/0.5 mL single-dose prefilled syringe. Amneal Pharmaceuticals (NASDAQ: AMRX) said it is launching the product immediately after receiving Competitive Generic Therapy designation.
The medicine references Somatuline Depot and is indicated for acromegaly, advanced gastro-entero-pancreatic neuroendocrine tumors and carcinoid syndrome. Its role varies by indication, including hormone control, progression-free survival in eligible patients and reduced need for rescue treatment.
Amneal Lanreotide Injection Enters a Large U.S. Market
Amneal cited annual U.S. sales of approximately $983 million for the reference product during the 12 months ended July 2026, based on IQVIA data. Reference-market sales are not a forecast of the revenue Amneal will capture; actual performance depends on pricing, competition, supply and payer adoption.
The company lists the approval and launch in its official product and press-release updates. A prefilled syringe can support administration convenience, but use remains governed by the approved label and healthcare-professional guidance.
Competitive Generic Status May Affect Market Entry
The FDA’s Competitive Generic Therapy pathway is intended for products where inadequate generic competition exists. The designation can provide development and review benefits, but it does not guarantee market share or commercial exclusivity in every circumstance.
For investors, the Amneal lanreotide injection adds a complex injectable product to the company’s portfolio and creates a near-term launch opportunity. The key measures will be supply reliability, formulary access, pricing and disclosed sales. Approval is a regulatory milestone; the commercial result will emerge only after the product enters regular use.
Because the product references an established medicine, competition may lower costs for the healthcare system while also placing pressure on unit pricing. Amneal’s manufacturing capacity and customer access will shape its eventual share.
